News View All News arrow-button

Dec 27, 2017

IFM CAB Member Michael Heneka Discusses Alzheimer’s Study in Alzforum


A study recently published in Nature by IFM Therapeutics scientific co-founder Dr. Eicke Latz and clinical advisory board member Dr. Michael Heneka demonstrated inflammation-driven, NLRP3-associated pathways may represent a novel therapeutic target for Alzheimer’s. 
Dr. Heneka was interviewed about the research and therapeutic implications for future Alzheimer’s treatments in Alzforum, a news site dedicated to advancing the development of diagnostics and treatments for Alzheimer’s disease and related disorders. View the full story, “Do Microglia Spread Aβ Plaques?”, on Alzforum. 

Media Contact

Amanda Sellers
Spectrum Science Communications